The presen invention relates to a method for identifying a subject at risk of developing hypertensive end organ damage, such as and in particular heart failure, comprising: (a) obtaining a biological sample of said subject; (b) determining the level of at least one non-myocytal marker in said sample; (c) comparing the level of said marker to a standard level; and (d) determining whether the level of the marker is indicative of a risk for developing hypertensive end organ damage. The non-myocytical marker preferably is galectin-3 or thrombospondin-2. IMAGE
展开▼